Michael Rafii
Medical Director, Alzheimer’s Therapeutic Research Institute · University of Florida College of Medicine
Credentials: · · ·
History
- Present
Alzheimer’s Therapeutic Research Institute Center · University of Florida College of Medicine
- 2003–2007
Neurology
Research
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Alzheimer s & Dementia · 2024 · 2,230 citations
Review · Nature Reviews Disease Primers · 2020 · 686 citations
Trial of Solanezumab in Preclinical Alzheimer's Disease
New England Journal of Medicine · 2023 · 359 citations
47 papers
22 papers
- RS
22 papers
14 papers
14 papers
13 papers · 11 as a resident
- FL
11 papers
11 papers
Grants
- 2025–2028
Life’s End Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY) Open-Label Extension (OLE) Study
National Institute on Aging · R01
PI · $4.1M · Medical University of South Carolina
- 2019–2026
Clinical Trials to Prevent Alzheimer's Disease in Down Syndrome
National Institute on Aging · R33
Contact PI · $6.9M · University of Southern California
- 2021–2026
Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome
National Institute on Aging · R01
PI · $1.2M · University of Southern California
- 2021–2024
Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome
National Institute on Aging · RF1
PI · $2.6M · University of California, San Diego
Clinical trials
- 2026–2028
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
Principal investigator · Not yet recruiting · Phase 4
Michael Rafii, MD, PhD
- 2022–2032
Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)
Principal investigator · Recruiting
Alzheimer's Disease and Related Disorders Association, Inc
- 2021–2027
Trial-Ready Cohort-Down Syndrome (TRC-DS)
Principal investigator · Recruiting
University of Southern California
- 2013–2017